BridgeBio Pharma, Inc. (BBIO) Debt by Year
BridgeBio Pharma, Inc. carried $2.0B in long-term debt against $570.1M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 359.0% from the prior fiscal year. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters BridgeBio Pharma, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BBIO Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K |
|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $2.0B+359.0% | $437.3M-2.0% | $446.4M+3.6% | $431.0M+0.1% | $430.8M+366.1% | $92.4M+0.7% | $91.8M+68.4% | $54.5M | N/A |
| Cash & Equivalents | $570.1M-16.3% | $681.1M+81.2% | $375.9M-0.2% | $376.7M-4.3% | $393.8M+10.6% | $356.1M-2.1% | $363.8M-16.6% | $436.1M+374.0% | $92.0M |
BBIO Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $2.7B | $2.7B | $2.0B+359.0% | $2.0B+360.2% | $0-100.0% | $0-100.0% | $437.3M-2.0% | $436.2M-1.2% | $435.4M-1.1% | $434.7M-0.2% | $446.4M+3.6% | $441.7M |
| Cash & Equivalents | $677.9M-9.5% | $879.9M+62.8% | $570.1M-16.3% | $643.0M+141.4% | $749.0M+83.6% | $540.6M+13.8% | $681.1M+81.2% | $266.3M-47.3% | $408.0M+34.9% | $475.2M+16.7% | $375.9M-0.2% | $505.2M+4.5% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More BridgeBio Pharma, Inc. financials
Frequently Asked Questions
What was BridgeBio Pharma, Inc.'s long-term debt in fiscal year 2025?
BridgeBio Pharma, Inc. carried $2.0B in long-term debt against $570.1M in cash and equivalents at the end of fiscal year 2025.
How fast is BridgeBio Pharma, Inc.'s long-term debt growing?
BridgeBio Pharma, Inc. (BBIO) long-term debt rose by 359.0% year over year, from $437.3M to $2.0B in fiscal year 2025.
What was BridgeBio Pharma, Inc.'s long-term debt in the most recent quarter?
BridgeBio Pharma, Inc. (BBIO) reported $2.7B in long-term debt in Q2 2026.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what BridgeBio Pharma, Inc. (BBIO) reported on that line in every period on record.